読み込み中
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
前日終値
$0.8239
+$0.0083 · +1.02%
日中の時刻はETです。市場データは遅延する場合があります。
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
日中レンジ
現在 $0.8239
52週レンジ
現在 $0.8239
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
45
適正価値
センチメント
56
まちまち
リスク
67
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
日中レンジ
現在 $0.8239
52週レンジ
現在 $0.8239
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 24.9万 USD | — |
| 売上原価 | — | — | — | 20.01万 USD | — |
| 粗利益 | — | — | — | 4.89万 USD | — |
| 研究開発 | 304.64万 USD | 347.17万 USD | 571.46万 USD | 415.22万 USD | 114.8万 USD |
| 販売・一般管理 | 390.65万 USD | 369.79万 USD | 459.66万 USD | 521.45万 USD | 208.22万 USD |
| 営業費用 | 695.3万 USD | 716.96万 USD | 1031.12万 USD | 936.67万 USD | 323.02万 USD |
| 受取利息 | 9.76万 USD | 14.58万 USD | 16.49万 USD | 8.97万 USD | 51.33万 USD |
| 支払利息 | 839 USD | 82.3万 USD | — | — | 36.75万 USD |
| 減価償却費と償却費 | 17.07万 USD | 19.91万 USD | 78.1万 USD | 30.64万 USD | 14.57万 USD |
| 営業利益 | −695.3万 USD | −716.96万 USD | −1031.12万 USD | −931.78万 USD | −323.02万 USD |
| 純利益 | −684.85万 USD | −771.78万 USD | −995.39万 USD | −929.69万 USD | −372.97万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
